TO DOWNLOAD THE DATASET, CLICK ON THE "Download" BUTTON

TO DOWNLOAD THE DATASET, CLICK ON THE "Download" BUTTON

TO DOWNLOAD THE DATASET, CLICK ON THE "Download" BUTTON

TO DOWNLOAD THE DATASET, CLICK ON THE "Download" BUTTON

The City of San Antonio's Open Data page for CoVID-19 surveillance data.

{{description}}

Background: Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations. Methods: This is a COVID-19 and Cancer Consortium (CCC19) registry-based retrospective cohort study of females with active or history of BC and laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection diagnosed between March 2020 and June 2021 in the US. Primary outcome was COVID-19 severity measured on a five-level ordinal scale, including none of the following complications, hospitalization, intensive care unit admission, mechanical ventilation, and all-cause mortality. Multivariable ordinal logistic regression model identified characteristics associated with COVID-19 severity. Results: 1,383 female patient records with BC and COVID-19 were included in the analysis, the median age was 61 years, and median follow-up was 90 days. Multivariable analysis revealed higher odds of COVID-19 severity for older age (aOR per decade, 1.48 [95% CI, 1.32–1.67]); Black patients (aOR 1.74; 95 CI 1.24–2.45), Asian Americans and Pacific Islander patients (aOR 3.40; 95 CI 1.70–6.79) and Other (aOR 2.97; 95 CI 1.71–5.17) racial/ethnic groups; worse ECOG performance status (ECOG PS ≥2: aOR, 7.78 [95% CI, 4.83–12.5]); pre-existing cardiovascular (aOR, 2.26 [95% CI, 1.63–3.15])/pulmonary comorbidities (aOR, 1.65 [95% CI, 1.20–2.29]); diabetes mellitus (aOR, 2.25 [95% CI, 1.66–3.04]); and active and progressing cancer (aOR, 12.5 [95% CI, 6.89–22.6]). Hispanic ethnicity, timing, and type of anti-cancer therapy modalities were not significantly associated with worse COVID-19 outcomes. The total all-cause mortality and hospitalization rate for the entire cohort were 9% and 37%, respectively; however, it varied according to the BC disease status. Conclusions: Using one of the largest registries on cancer and COVID-19, we identified patient- and BC-related factors associated with worse COVID-19 outcomes. After adjusting for baseline characteristics, underrepresented racial/ethnic patients experienced worse outcomes compared to Non-Hispanic White patients.

Baseline demographic characteristics among adults with COVID-19 infection.

{{description}}

United States AQI: Texas: San Antonio-New Braunfels: NO2 data was reported at 40.000 Index in 31 Jan 2025. This records a decrease from the previous number of 41.000 Index for 30 Jan 2025. United States AQI: Texas: San Antonio-New Braunfels: NO2 data is updated daily, averaging 16.000 Index from Jan 1980 (Median) to 31 Jan 2025, with 11998 observations. The data reached an all-time high of 54.000 Index in 01 Dec 2017 and a record low of 1.000 Index in 28 Jun 2020. United States AQI: Texas: San Antonio-New Braunfels: NO2 data remains active status in CEIC and is reported by United States Environmental Protection Agency. The data is categorized under Global Database’s United States – Table US.ESG.E001: Air Quality Index and Air Pollutants. [COVID-19-IMPACT]

The City of San Antonio's Open Data page for CoVID-19 vaccination data.

According to Cognitive Market Research, the global Emerging Cancer Vaccines market size is USD XX million in 2024 and will expand at a compound annual growth rate (CAGR) of 12.50% from 2024 to 2031.

North America held the major market of more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.7% from 2024 to 2031.
Europe accounted for a share of over 30% of the global market size of USD XX million.
Asia Pacific held the market of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.5% from 2024 to 2031.
Latin America market of more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.9% from 2024 to 2031.
Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.2% from 2024 to 2031.
The Genetic vaccines held the highest Emerging Cancer Vaccines market revenue share in 2024

Market Dynamics of Emerging Cancer Vaccines Market

Key Drivers for Emerging Cancer Vaccines Market

Increasing Prevalence of Cancer to Propel the Market Revenue Growth

One of the major factor that propel the emerging cancer market is rising prevalence of cancer across the globe as the traditional therapy such as chemotherapy and radiation therapy often have a significant side-effets. This side effects turn medical personnel for the R&D of cancer vaccines, which anticipated to drive the penetration of market revenue growth. For instance, according to the estimates by American Cancer Society, around 20 million cancer cases were newly diagnosed and 9.7 million people died from the cancer globally in 2022. This number of cancer cases is projected to grow 35 million by 2050. Thus, the aforementioned stats support the market growth.

Rising Clinical Trials to Boost Market Growth

The growing clinical trials are expected to propel the market growth during the forecast period. For instance, in December 2023, nixa Biosciences, Inc., a biotechnology business that specializes in cancer therapy and prevention, recently released updated and fresh positive data from their breast cancer vaccine's Phase 1 clinical study. The trial is being carried out with financial support from a grant from the U.S. Department of Defense in association with Cleveland Clinic.G. Thomas Budd, M.D., a staff physician at Cleveland Clinic Cancer Institute and the study's principal investigator, presented the data at the 2023 San Antonio Breast Cancer Symposium in a poster titled "Phase I Trial of alpha-lactalbumin vaccine in high-risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC.

Source: https://www.prnewswire.com/news-releases/anixa-biosciences-and-cleveland-clinic-present-positive-new-data-from-phase-1-study-of-breast-cancer-vaccine-302007568.html.

Restraint Factor for the Emerging Cancer Vaccines Market

Complexity of Cancer Immunology to Limit the Market Growth

The complexity of cancer immunology is expected to hamper the market growth during the forecast period. As cancer disease is complex and heterogeneous in nature, and immune systems response to these disease is also very complex in nature. The R&D of the effective cancer vaccines demanding a good knowledge of tumor biology, immune evasion mechanisms, and the interplay between cancer cells and the immune system. The complex nature cancer immunology is the major challenge in identifying suitable vaccine targets and optimizing vaccine design, which may impede the development of theraupeutic treatment of cancer such as vaccines.

Impact of Covid-19 on the Emerging Cancer Vaccines Market

The COVID-19 pandemic had a mix impact on the emerging cancer vaccines market. The mRNA based vaccines manufactured by the global company such as Pfizer-BioNTech and Moderna, has brought attention to the potential of mRNA technology in the production of vaccines. As the same technology is used to modified target cancer-specific antigens, which has increased demand and funding for mRNA-based cancer vaccines. Furthermore, the COVID-19 has raised awareness of the significance of immunotherapy and vaccinations in fight aginst various disease including cancer, in...

They are women who migrated after 2018, considered by UNHCR as Venezuelans displaced abroad, people who are likely to be in need of international protection, requiring protection against forced returns and access to basic services, regardless of age, educational level and migration status. The population is a database of migrant population of which 2,495 are women of legal age who migrated from Venezuela between April and May 2019, through the migratory corridor between Ureña/San Antonio and Villa del Rosario Cúcuta, digesting to different destinations in South America including Colombia. It is a population that has continued to be linked to the High Border Studies Group (ALEF) of the Simon Bolivar University, because it has been consulted for various studies to study the living conditions in the host countries. And in this study we want to make visible the need to understand the conditions of female migration in terms of access to and exercise of SRR. The sampling frame design was non-probabilistic. An online survey was applied to 2495 women during April 1 to June 3, 2021, obtaining the response of 86 women (sample for this study). 3.5%

Demographics, clinical features and underlined health conditions of the cohort.

United States AQI: Texas: San Antonio-New Braunfels: Ozone data was reported at 49.000 Index in 16 May 2025. This records a decrease from the previous number of 101.000 Index for 15 May 2025. United States AQI: Texas: San Antonio-New Braunfels: Ozone data is updated daily, averaging 38.000 Index from Jan 1980 (Median) to 16 May 2025, with 16492 observations. The data reached an all-time high of 159.000 Index in 08 Jun 2017 and a record low of 5.000 Index in 22 Mar 2020. United States AQI: Texas: San Antonio-New Braunfels: Ozone data remains active status in CEIC and is reported by United States Environmental Protection Agency. The data is categorized under Global Database’s United States – Table US.ESG.E: Air Quality Index and Air Pollutants. [COVID-19-IMPACT]

United States AQI: Texas: San Antonio-New Braunfels: SO2 data was reported at 0.000 Index in 30 Jun 2023. This stayed constant from the previous number of 0.000 Index for 29 Jun 2023. United States AQI: Texas: San Antonio-New Braunfels: SO2 data is updated daily, averaging 0.000 Index from Jan 1980 (Median) to 30 Jun 2023, with 7484 observations. The data reached an all-time high of 70.000 Index in 04 Aug 2017 and a record low of 0.000 Index in 30 Jun 2023. United States AQI: Texas: San Antonio-New Braunfels: SO2 data remains active status in CEIC and is reported by United States Environmental Protection Agency. The data is categorized under Global Database’s United States – Table US.ESG.E001: Air Quality Index and Air Pollutants. [COVID-19-IMPACT]